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Remote ischemic conditioning 
A B S T R A C T   
During myocardial ischemia, timely reperfusion is critical to limit infarct area and the overall loss of cardiac 
contractile function. However, reperfusion further exacerbates the damage of the ischemic heart. This type of 
injury is known as ischemia-reperfusion injury (IRI). Ischemic conditioning is a procedure which consists of brief 
cycles of ischemia and reperfusion in order to protect the myocardium against IRI. Remote ischemic conditioning 
(RIC), namely transient brief episodes of ischemia at a remote site before a subsequent damaging ischemia/ 
reperfusion procedure of the target organ (e.g., the heart), protects against IRI. However, how the stimulus of RIC 
is transduced from the remote organ to the ischemic heart is still unknown. Recently, extracellular vesicles (EVs) 
have been proposed to have a role in the RIC procedure. The endothelium releases EVs and is also one of the 
tissues mostly exposed to EVs during their journey to the target organ. Moreover, EVs may have important roles 
in angiogenesis and, therefore, in the remodeling of post-ischemic organs. Here we analyze how EVs may 
contribute to the overall cardioprotective effect and the implication of the endothelium and its EVs in RIC 
mediated acute cardioprotection as well as in angiogenesis.   
1. Introduction 
The paradigm of cardioprotection induced by ischemic pre-
conditioning (IPC) was established by Murry and colleagues [1]. These 
authors demonstrated that brief cycles of 5 min coronary occlusion 
interspersed with 5 min of reperfusion immediately prior to 40 min of 
coronary occlusion were able to significantly reduce infarct size (IS). 
Subsequently remote ischemic conditioning (RIC) was described [2]. 
Unlike IPC, which protects only those districts directly subjected to 
initial ischemia by coronary occlusion, in RIC the ischemic insult is 
applied to distant areas within the heart or distant organs. Among 
distant organs limbs [3] are included. RIC gained popularity for this 
intriguing feature and it is believed a more applicable type of 
conditioning for cardioprotection in humans. RIC can be applied before 
ischemia, that is remote preconditioning (RIPC), during organ ischemia, 
namely remote per-conditioning (RIPerC) and/or after organ ischemia, 
that is remote post-conditioning (RIPostC). All these procedures, 
collectively known as RIC, showed similar cardioprotective effects [4]. 
Several evidence suggest that many organs can undergo RIC in order 
to protect the heart from ischemia/reperfusion (I/R) injury (IRI). 
Indeed, cardioprotection can be evoked by ischemic episodes in distant 
organs, such as liver [5], small intestine [6], and kidney [7]. Different 
interesting mechanisms have been proposed to explain the car-
dioprotective effect of RIC [8] including: i) the RIC as a trigger of specific 
mediators in the preconditioned remote organ/limb, ii) the transfer of 
such mediators from remote organ/limb to the heart, and finally iii) the 
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modulation end effectors within the heart enhancing its resistance to 
sustained IRI. 
Recently, extracellular vesicles (EVs) have been proposed as poten-
tial mediators of cardioprotective signals of RIC [9] (Fig. 1) and po-
tential carriers of protective signals in general [10]. In particular, in the 
context of chronic ischemic myocardial disease, intramyocardial treat-
ment with human EVs may increase the perfusion of post-ischemic 
myocardial tissue by inducing arteriolar and capillary growth. It 
seems that the EVs are able to activate the Akt/eNOS and mitogen- 
activated protein kinase signaling pathways resulting in increasing 
both the stroke volume and cardiac performance. However, contrasting 
results are reported about the ability to induce changes in vascular 
density and to improve cardiac function under conditions of chronically 
ischemic myocardium and/or diet-induced metabolic syndrome (MS) 
[11–14]. 
In accordance with these studies, the main goal of this review is to 
recap the most recent knowledge implicating EVs in RIC mediated- 
cardioprotection, focusing on the role of endothelium-derived EVs and 
their involvement in angiogenesis. Indeed, in addition to producing 
most of the circulating EVs, the endothelium is constantly exposed to 
circulating EVs not only at the interfaces with remote organs and the 
target tissue in general, but also throughout the vasculature of the whole 
body. These features make the endothelium a fundamental mediator of 
the cross-talk between the remote organ and the heart and so a potential 
mediator of the RIC and subsequent angiogenesis. 
2. Extracellular vesicles: Classification, content and biogenesis 
EVs are lipid bilayer-coated particles secreted by different cell types 
into the extracellular space and thereafter into the circulation. However, 
EVs can be also found in several other body fluids, such as saliva, urine, 
breast milk, and cerebrospinal [15–18]. EVs can be mainly classified 
based on their size in small (<100 nm or < 200 nm) and medium/large 
EVs (>200 nm) and based on their origin in exosomes and micro-vesicles 
[19] (Fig. 2). Although a third category of EVs has been suggested, 
named apoptotic bodies, their genesis and function deeply differ from 
those of the two former categories and they are not thought to act as 
humoral factors in intercellular communication [20]. EVs (micro-vesi-
cles and exosomes) are broadly enriched with several bioactive mole-
cules, e.g., lipids, proteins, and nucleic acids, such as messenger RNAs 
(mRNAs) and non-coding RNAs [21,22]. However, several EV features 
depend on the microenvironment from which they are secreted [23]. For 
this and other reasons, besides being involved in both cardiovascular 
physiology and pathophysiology [24,25], EVs have been proposed as 
potential diagnostic and/or prognostic biomarkers, in different clinical 
settings [26,27]. 
2.1. Micro-vesicles (medium/large EVs) 
Micro-vesicles, equally known as micro-particles or ectosomes, have 
a diameter ranging from 100 to 1000 nm [19]. They are released upon 
calcium-dependent enzyme recruitment that modify the asymmetry of 
the plasma membrane and elicit cytoskeleton changes. In particular, the 
protrusion of phosphatidylserine from the inner to the outer side of the 
membrane via the aminophospholipid translocases (mainly flippases 
and floppases) is triggered by the increase in intracellular calcium levels. 
Moreover, the calcium signal engages calpain to further destabilize the 
plasma membrane actin-cytoskeleton anchorage, thereby inducing these 
specialized plasma membrane regions to bud outwards and originate 
EVs [22]. 
2.2. Exosomes (small EVs) 
Exosomes are the smallest class of EVs, ranging from 30 to 150 nm, 
which are produced in the endosomal compartment [21]. Briefly, newly 
formed endocytic vesicles fuse with early endosomes (EEs), which, in 
turn, gradually mature into late endosomes (LEs). Inward budding of LE 
membrane results in the formation of intraluminal vesicles (ILVs) and 
LEs are, therefore, also known as multivesicular bodies (MVBs). MVBs 
can then be targeted to lysosomes for degradation or move to and fuse 
with the plasma membrane, thereby releasing ILVs as exosomes (Fig. 2). 
The formation of ILVs occurs in specific regions of the LE membrane 
Fig. 1. Schematic model representing the putative cardioprotective mechanism of Remote Ischemic Conditioning (RIC). EVs (Extracellular vesicles) are 
released into the circulation upon RIC and home to the heart where they exert their protective role. 
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enriched with tetraspanins and requiring the Endosomal Sorting Com-
plex Required for Transport (ESCRT), which acts in concert with 
accessory proteins, such as Alix and the tumor susceptibility gene 101 
(TSG101). Yet, exosomes are enriched with heat shock proteins (HSP70 
and HSP90) and tetraspanins (CD9, CD63 and CD81) and express 
markers of their cell of origin [20,21]. 
3. EVs and endothelium in cardioprotection 
Although their role is still controversial, several studies have sug-
gested endothelial-derived EVs (ECs-EVs) as a novel tool for the treat-
ment of cardiovascular diseases [28] (Table 1). One of the first studies 
suggesting the potential role of ECs-EVs in RIC mediated car-
dioprotection was performed by Davidson and colleagues [29]. Using 
human umbilical vein endothelial cells (HUVECs)-derived EVs, they 
demonstrated that the exposure of primary cardiomyocytes to EVs re-
duces IRI-induced cellular damage paving the way to identify ECs-EVs as 
crucial mediators of cardioprotection in response to RIC. In fact, in an ex 
vivo model, Giricz et al. [9] demonstrated that the heart subjected to IPC 
releases EVs able to protect the naïve heart, thus simulating RIC. These 
two studies provide the proof-of-concept that conditioning procedures 
almost double the release of EVs both in vitro and ex vivo (isolated 
perfused rat heart). Intriguingly, EVs obtained by preconditioned 
HUVECs only exert their protective effect when given in a dose- 
dependent manner, reflecting the trend observed after precondition-
ing. On the other hand, Jeanneteau et al. [30] report that EV number 
after RIC does not increase either in rats or in humans. However, the 
relative ECs-EV number (CD54+ and CD146+) and the pro-coagulant 
Annexin V+ EVs increased in rats, after 10 min of limb ischemia fol-
lowed by 10 min of reperfusion, and in humans after three cycles of 5 
min ischemia followed by 5 min reperfusion. Treatment with pre-
conditioned rat derived EVs did not show any significant improvement 
in the IRI model with an ischemic area pretty similar to the control group 
[30]. 
The paucity of studies and their heterogeneity does not allow to draw 
clear-cut conclusions on the role of ECs-EVs as mediators of RIC. In 
addition, whether the endothelium should be considered a RIC target, a 
mediator, or both, is even harder to assert. For instance, Chen and col-
laborators [31] demonstrated that rats treated with RIC-derived EVs 
improved cell remodeling, heart function related parameters, and 
angiogenesis after myocardial infarction. RIC treatment consisted in 10 
cycles of 2 min reperfusion and 2 min bilateral hindlimb ischemia using 
tourniquets, at 20-s intervals and the animals were injected with RIC EVs 
every three days up to 28 days. The investigators also demonstrated that 
HSP70 enriched in EVs is a crucial mediator. On the other hand, no 
experiment assessing the cellular origins of these circulating EVs was 
performed, making it difficult to establish which and how much 
different tissues contribute to circulating EVs and, therefore, to RIC. 
Indeed, several cell types produce EVs. ECs, macrophages, fibroblasts 
and cardiomyocytes, are the primary sources of EVs locally in the heart 
[25–32]. However platelets [33], mesenchymal stem cells (MSCs) [34] 
and various cell types produce their own EVs. In this regard, a very 
recent study reported that upon pretreatment with a Chinese medicine, 
Tongxinluo, cardiomyocytes release EVs which protect cardiac micro-
vascular ECs after 18 h hypoxia followed by 2 h reoxygenation by 
activating eNOS, thus, unveiling a cardioprotective mechanism which 
involves the cross-talk between cardiomyocytes and ECs. The mecha-
nism was also established in vivo. The authors suggested that car-
dioprotection relies on changes in the EVs content upon Tongxinluo 
treatment. In particular, EVs were found enriched in specific long non- 
coding RNAs which downregulates miR-145-5p and leads to eNOS 
activation [35]. 
3.1. Microenvironment impacts on EVs 
Several groups reported that pharmacological modulation of the 
microenvironment can dictate EVs' features. For example, cardiac pro-
genitor cells release anti-hypoxic EVs upon Ticagrelor administration 
[36], whereas the efficacy of MSCs-derived EVs in the treatment of acute 
myocardial infarction is enhanced by Atorvastatin, likely favoring 
endothelial function through the upregulation of the long non-coding 
RNA H19 [37]. Intriguingly, an inflammatory environment could also 
affect the production of protective EVs. For instance, we demonstrated 
that the interaction between endothelial-derived EVs and the coronary 
endothelial layer is necessary to trigger cardioprotection via the acti-
vation of the MEK1/2/eNOS/GC pathways. Yet, ECs pre-exposed to 
interleukin 3 (IL-3) release EVs enriched in the eNOS-antagonist cav-
eolin-1 that may hamper EV cardioprotective properties [38]. Of note, 
Fig. 2. Schematic representation of EVs biogenesis. A) Micro-vesicles biogenesis. B) Exosomes biogenesis. SER (Smooth endoplasmic reticulum); MVB (Multi-
vesicular body). 
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Kang and colleagues [39] have found that adipose derived-stem cells, 
when cultured in endothelial differentiation medium, release miR-31 
enriched EVs that enhance angiogenesis by targeting and down-
regulating the factor-inhibiting hypoxia-inducible factor-1 (HIF-1). 
However, a different study reported that, upon hypoxia/reoxygenation 
treatment (12 h in hypoxic buffer into a hypoxic chamber and then 
reoxygenated for 4 h), HUVECs produce apoptotic and hypoxic EVs, 
promoting apoptosis and oxidative stress in H9c2 cells in vitro [40]. 
Thus, RIC could positively modulate the microenvironment, leading not 
only to induce the release of protective EVs [29] in situ, but also to exert 
direct effect at the site of the maneuver application [41]. Nevertheless, 
we must consider that, besides the remote conditioning effects 
Table 1 
Mechanisms of modulation of cardioprotection and angiogenesis by EVs.  
References Model EV Origin EV Content Main results 
Main topic: cardioprotection 
[9] Rat Hearts Ex vivo I/R 30′ + 2 
h 
EVs from ex vivo rat hearts 
subjected to IPC 
NC EVs reduce infarct size 
[29] Primary Rat 
Cardiomyocytes 
H/R 
2 h30′ + 30’ 
EVs from HUVECs subjected to 
30′ hypoxia 
NC EVs protect against hypoxia via ERK1/2 
[30] Rats In vivo IR 
40′ + 2 h 
EVs from rats subjected to RIC NC EVs do not reduce infarct size 
[31] Rats In vivo IR EVs from rats subjected to RIC NC EVs decrease collagen deposition and infarct 
ratio, increase angiogenesis and increase the 
expression of eNOS, HIF1α, Angiopoietin-1, 
VEGF and Hsp70 
[31] CMVECs H/R 
12 h + 24 h 
EVs from rats subjected to RIC NC EVs increase cell proliferation and migration, 
increase ratio of G1 cells, inhibit apoptosis, 
increase tube formation and increase the 
expression of Hsp70 
[35] CMECs H/R 
18 h + 2 h 
EVs from Tongxinluo- 
pretreated cardiomyocytes 
subjected to H/R (18 h/2 h) 
Linc-ROR➔ downregulation 
miR-145-5p ➔ activation of 
p70s6k1 ➔ eNOS activation 
EVs reduce cell death, increase eNOS 






EVs from hCPCs pretreated 
with ticagrelor (72 h) 
NC EVs decrease cell death, attenuate intracellular 
HIF1α, increase pERK42/44 (measured 5 min 
after the end of EV treatment) 
[37] HUVECs Hypoxia 
12 h 
EVs from Atorvastatin-treated 
MSCs 
LncRNA H19 ➔ regulates miR- 
675 expression ➔ activation of 
VEGF and ICAM-1 
EVs increase tube length and migration rate, 
decrease apoptosis 
[37] Rats In vivo I/R EVs from Atorvastatin-treated 
MSCs 
LncRNA H19 ➔ regulates miR- 
675 expression ➔ activation of 
VEGF and ICAM-1 
EVs increase cardiac functional recovery, 
increase angiogenesis, decrease inflammation 
(lower IL-6 and TNFα levels) 
[38] H9C2 H/R 
2 h + 1 h 
EVs from IL-3 treated-HUVECs 
or EV from HUVECs 
Caveolin-1 IL-3-EVs do not improve cell viability, while EVs 
do 
[38] Rat Hearts Ex vivo I/R 30′ +
60′
EVs from IL-3 treated-HUVECs 
or EV from HUVECs 
Caveolin-1 IL-3-EVs do not reduce infarct size, while EVs do 
[40] H9c2 Normoxia EVs from HUVECs subjected to 
H/R (12 h/4 h) 
NC EVs reduce viability, increase ROS formation and 
increase p38 and JNK1/2 phosphorylation 
[50] Primary Rat 
Cardiomyocytes 
H/R 
3 h + 1 h 
EVs from hyperglycemic 
HUVECs, hyperglycemic rats 
and diabetic patients 
CD81 and HSP70 EVs from hyperglycemic conditions lose the 
ability to protect (the viability of cardiomyocytes 




2 h30’ + 20 h 
EVs from normoglycemic and 
diabetic rats subjected to RIC 
NC Only EVs from normoglycemic rats protect 
against H/R  
Main Topic: Angiogenesis 
[12] Pigs In vivo I/R 
with an ameroid 
constrictor 
EVs from MSCs NC EVs increase capillary and arteriolar density, 
increase CO and SV, increase phosphorylation of 
MAPK and eNOS 
[13] Pigs with High Fat 
Diet 
In vivo I/R with an 
ameroid 
constrictor 
EVs from MSCs NC EVs increased arteriolar but not capillary 
density, increased CO and SV 
[32] HMECs Normoxia (in 
vitro) and Matrigel 
plug (in vivo) 
EVs from HMECs MiR-214 ➔ stimulates 
angiogenic program 
EVs increase tube length, increase migration and 
angiogenic sprouts in vitro; stimulate neovessel 
formation in vivo 
[39] HUVECs Normoxia EVs from ASCs preconditioned 
with endothelial 
differentiation medium 
MiR-31 ➔ targets factor- 
inhibiting HIF1 
EVs increase migration and tube formation 
[58] HUVECs Normoxia EVs from MSCs subjected to 
72 h hypoxia 
NC EVs increase proliferation, migration and tube 
formation 
[58] Rats In vivo I/R 30’ EVs from MSCs subjected to 
72 h hypoxia 
NC EVs reduce infarct size, improve cardiac 
function, increase angiogenesis 
[61] HUVECs Normoxia EVs from HUVECs MMP-2 and MMP-9 EVs improve migration and tubulogenesis 
[62] HUVECs Normoxia EVs from HUVECs and 
HDMECs 
Downregulation of miR-106b +
upregulation of lncRNA HOTAIR 
and MALAT1 
EVs increase vascularization bioactivity 
[66] HMECs, HUVECs Normoxia EVs from MSCs mRNA for PI3K ➔ Akt and NO EVs improve proliferation and migration via 
Akt/NO pathway 
[67] RMECs Normoxia EVs from ECFCs >20 miRNAs ➔ stimulate 
angiogenesis 
EVs increase cell migration 
[68] Mice In vivo I/R 
30’ 
EVs from MSCs subjected to 
hypoxia for 24 h 
MiR-486-5p ➔ targets MMP19 EVs improve cardiac function, enhance vascular 
density, decrease infarct size 
NC = not considered; Other acronyms and abbreviations as in the text. 
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[9,42,43], the presence, content, and EV characteristics may be influ-
enced by several different conditions [33,44], including acute coronary 
syndrome (in patients/animal-models) and mechanical stimulation 
[45,46], which could hamper their cardioprotective action [10,33]. 
4. EVs, metabolic syndrome and remote conditioning 
Along with microenvironmental cues, sex [47] and comorbidities, 
such as metabolic syndrome (MS), dictates EV features mainly impacting 
on their cargo. Given the role played by diabetes in hampering car-
dioprotection and angiogenesis, here we focus on type 1 and 2 diabetes 
mellitus (T1DM and T2DM, respectively) [48]. The impact of other 
comorbidities on EVs are discussed in a recent review [47]. It seems that 
EVs lose their protective properties in diabetes. Indeed, it has been re-
ported that small EVs from adipocytes of T2DM mice may have a role in 
the transduction of pathological signals resulting in the exacerbation of 
myocardial IRI. The same results were obtained with EVs derived from 
human T2DM and reversed by downregulating miR-130b-3p, suggesting 
a new standpoint in the treatment of T2DM [49]. Davidson and col-
leagues demonstrated that EC-EVs lose their cardioprotective activity 
when taken from T2DM rats/patients [50]. This may explain, at least in 
part, the lack of protection of RIC in diabetic settings [51]. Surprisingly, 
while EVs from diabetic animals were found ineffective in transducing 
protection, their removal worsens hypoxia/reoxygenation-induced 
damage. As in T2DM, the role of EVs in T1DM is controversial. 
Various studies suggest that EVs may contribute to the autoimmune 
process by carrying autoantigens resulting in β-cell dysfunction [52], 
whereas others support the anti-inflammatory effect of EVs occurring in 
TD1M [53]. Interestingly, it has been reported that the EV number is 
increased in T1DM compared to T2DM and healthy subjects [54]. 
5. Endothelium, EVs and angiogenesis 
Angiogenesis is a well-regulated process that plays a fundamental 
role in the embryo development, and in vascular homeostasis of mature 
organisms, during tissue regeneration and repair. The angiogenic pro-
cess occurs in various pathological conditions including inflammation 
and the post-ischemic phases of vascularization [55]. Indeed, post- 
ischemic vascularization, which is mainly driven by angiogenesis, is 
essential to rescue organ function upon an ischemic event and is the final 
target of a vast array of strategies, collectively denoted as therapeutic 
angiogenesis [56]. EVs deriving from different MSC sources can stimu-
late endothelial cell proliferation and tube formation in vitro and in-
crease capillary density and local blood perfusion in small and large 
animal models of acute and chronic myocardial ischemia [12,57,58] 
(Table 1). However, the route of EV delivery (intramyocardial vs. 
intravenous) is crucial to boost in vivo angiogenesis under conditions of 
chronic myocardial ischemia [12]. Furthermore, in a setting of diet- 
induced metabolic syndrome, intramyocardial delivery of EVs resulted 
in an increased arteriolar, but not capillary density [13]. Since different 
EC subpopulations may exist within the same vascular network [59], it is 
likely that MSCs-derived EV content can be sensed or not as a pro- 
angiogenic input depending on the vascular position of recipient EC 
(arteriolar or capillary). The above evidence, however, suggests that 
vascular ECs undergo angiogenesis by EVs. Furthermore, endothelial- 
derived EVs could directly contribute to transduce RIC into a pro- 
angiogenic output [60]. Early work demonstrated that cultured 
HUVECs shed EVs, ranging from 300 to 600 nm and containing matrix 
metalloprotease-2 (MMP-2) and MMP-9, which autocrinally stimulate 
endothelial migration [61]. Further studies unveiled that ECs-EVs pro-
moted EC migration and tube formation by the horizontal transfer of 
miR-214, which was also required to promote EV-dependent neo-
vascularization in vivo [32]. The proof-of-concept that vascular ECs may 
release pro-angiogenic EVs has been recently described in [62]. This 
report demonstrated that HUVECs and human dermal microvascular 
endothelial cells (HMECs) pre-treated with ethanol (0–200 mM) release 
EVs that are, in turn, able to promote endothelial migration in vitro and 
neovascularization in vivo. This response involves two pro-angiogenic 
long non-coding RNAs, i.e., MALAT1 and HOTAIR, in ECs-EVs [62] 
and is consistent with the emerging notion that moderate alcohol con-
sumption could exert a beneficial effect on endothelial function [63]. 
Paradoxically, the circulating pro-angiogenic EVs detected after intense 
physical exercise are mainly secreted by pro-coagulant rather than 
vascular ECs [64]. However, a powerful source of EVs in the cardio-
vascular system is represented by endothelial colony forming cells 
(ECFCs), which represent endothelial progenitor cells (EPC) truly 
belonging to the endothelial lineage [65]. ECFCs are mobilized in pe-
ripheral blood and redirected towards ischemic tissues to stimulate local 
angiogenesis and physically engraft within neovessels, according to the 
process known as vasculogenesis [65]. An early study demonstrated that 
the horizontal transfer of a precise subset of mRNAs enabled ECFCs to 
activate an angiogenic program in HUVECs and HMECs [66]. ECFCs- 
derived EVs stimulate in vitro proliferation and tube formation in both 
EC types and promote neovascularization in vivo [66]. The pro- 
angiogenic effect of ECFCs-derived EVs was mediated by the transfer 
of mRNAs encoding for PI3K in recipient ECs, which led to Akt activa-
tion and eNOS phosphorylation [66]. A recent report confirmed that 
ECFCs-derived EVs, whose size ranges from 60 to 1500 nm, convey ≈20 
mRNAs, including miR-486-5p and miR-26A, which stimulate retinal 
microvascular EC migration in vitro [67]. Furthermore, the intravitreal 
injection of these ECFCs-derived EVs reduced the avascular area in a 
mouse model of oxygen-induced retinopathy [67]. Recently, treatment 
with either miR-486-5p overexpressing EVs or EVs derived from 
hypoxia-preconditioned MSCs promoted angiogenesis and cardiac re-
covery in a non-human primate acute myocardial infarction (AMI) 
model. In this model MMP19-VEGFA fibroblast cleavage signaling 
contributed to angiogenesis [68]. 
Notably, RIC has been shown to stimulate EPC recruitment in the 
ischemic myocardium in rabbits, thereby increasing capillary density 
and coronary blood flow [69]. Likewise, RIC was proven effective in 
enhancing the levels of circulating EPCs in a rat model of hindlimb 
ischemia [70]. Although focused on EPC populations belonging to the 
myeloid lineage [65], these preliminary reports pave the way to future 
research on large animal (which exhibit higher ECFC levels) models of 
AMI with the aim to assess whether RIC may induce myocardial revas-
cularization through ECFCs-derived EVs. To investigate whether RIC is 
able to stimulate vascular ECs, at local (i.e., at the site of conditioning) 
or distant (i.e., in the ischemic myocardium) sites, to release pro- 
angiogenic EVs would be also of particular interest. 
6. Conclusion 
RIC is a powerful tool to treat IRI, positively affecting the final 
infarcted area after myocardial ischemia and reperfusion. Despite the 
promising results on the potential cardioprotective effect of RIC, the 
mechanisms still remain elusive. Among proposed candidates, EVs 
caught the attention of many research groups. Once EVs are released in 
the circulation, they are conveyed from the preconditioned limb or 
organ to the heart where they exert their protective function. However, 
there is not enough clear-cut evidence to establish the role of endothe-
lium in RIC. Besides a few number of studies and their discordant results, 
an important issue concerns the huge variability in the protocols of 
preconditioning. As reported in the previous paragraph, the timing used 
in RIC protocols are very different from each other not only in vivo but 
also in vitro, where the use of hypoxic buffers in tandem with the in-
cubation of cells into hypoxic chambers adds further variability. The 
standardization of such methods should be among the future challenges. 
Another point is EV characterization. As aforementioned, almost every 
cell type produces EVs, an aspect that should be taken into consideration 
particularly when complex animal models are used. EVs characteriza-
tion based on their physical parameters should be integrated with 
methodologies updating their cell of origin. On the other hand, the use of 
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HUVECs as an endothelial model is surely convenient but not so repre-
sentative. Studies on other cell cultures such as primary endothelial cells 
isolated from the main vessels or adult vascular bed in general should be 
carried out. Moreover, the production and the release of EVs from these 
endothelial cell cultures may not completely resemble the in vivo con-
dition in the presence of comorbidities which could affect endothelial 
function by modifying their circulating level and content. In this view, 
circulating ECFCs might represent an alternative, but reliable, model to 
investigate whether and how cardiovascular risk factors hamper the 
ability of endothelial cells to release cardioprotective EVs. Moreover, 
ECFCs could themselves represent the cellular vehicle recruited by RIC 
to deliver pro-angiogenic EVs to the ischemic organ. 
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[5] M. Barteková, Z. Sulová, D. Pancza, et al., Proteins released from liver after 
ischaemia induced an elevation of heart resistance against ischaemia-reperfusion 
injury: 2. Beneficial effect of liver ischaemia in situ, Gen. Physiol. Biophys. 23 
(2004) 489–497. 
[6] R.G. Schoemaker, C.L. Van Heijningen, Bradykinin mediates cardiac 
preconditioning at a distance, Am. J. Physiol. Heart Circ. Physiol. 278 (2000) 
1571–1576, https://doi.org/10.1152/ajpheart.2000.278.5.h1571. 
[7] V. Diwan, R. Kant, A.S. Jaggi, et al., Signal mechanism activated by erythropoietin 
preconditioning and remote renal preconditioning-induced cardioprotection, Mol. 
Cell. Biochem. 315 (2008) 195–201, https://doi.org/10.1007/s11010-008-9808-3. 
[8] P. Kleinbongard, A. Skyschally, G. Heusch, Cardioprotection by remote ischemic 
conditioning and its signal transduction, Pflugers Arch. - Eur. J. Physiol. 469 
(2017) 159–181, https://doi.org/10.1007/s00424-016-1922-6. 
[9] Z. Giricz, Z.V. Varga, T. Baranyai, et al., Cardioprotection by remote ischemic 
preconditioning of the rat heart is mediated by extracellular vesicles, J. Mol. Cell. 
Cardiol. 68 (2014) 75–78, https://doi.org/10.1016/j.yjmcc.2014.01.004. 
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